Illumina, Inc. (ILMN) January 25, 2012 7:00 am ET Executives Daniel O'Day - Chief Executive Officer of Roche Molecular Diagnostics and President of Roche Molecular Diagnostics Severin Schwan - Chief Executive officer Alan Hippe - Chief Financial and IT Officer Analysts Vincent Meunier - Exane BNP Paribas, Research Division Gbola Amusa - UBS Investment Bank, Research Division Keyur Parekh - Goldman Sachs Group Inc., Research Division Luisa Hector - Crédit Suisse AG, Research Division Sachin Jain - BofA Merrill Lynch, Research Division Alexandra Hauber - JP Morgan Chase & Co, Research Division Quintin J. Lai - Robert W. Baird & Co. Incorporated, Research Division Michael Leacock - RBS Research William R. Quirk - Piper Jaffray Companies, Research Division PresentationOperator
Good morning or good afternoon. Welcome to the Roche conference call regarding the Illumina transaction. I'm Dino, the Chorus Call operator. [Operator Instructions] And the conference is being recorded. [Operator Instructions] The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Dr. Severin Schwan, CEO. Please go ahead, sir. Severin Schwan Welcome to everybody, and thank you for joining our call, which is going to last for about one hour. This is Severin speaking, and with me today, Alan Hippe, our Chief Financial Officer; and Dan O'Day, Chief Operating Officer of Roche Diagnostics. Illumina is a great successful company, and we are excited to share with you the background of this planned acquisition. At the beginning, just let me shortly put this transaction into context. An important element of today's success of Roche Diagnostics is our breadth and depth of various key measuring technologies. They allow us to develop and market a broad range of diagnostic tests from molecular diagnostics to serum work area or tissue diagnostic testing. The completeness of our offering is important, both for our customers and Roche.